Hrt Financial LP Coherus Bio Sciences, Inc. Transaction History

Hrt Financial LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$1.59 - $3.85 $373,772 - $905,046	235,077 New	235,077 $782,000
Q2 2023 Aug 11, 2023	BUY	$3.79 - $8.3 $886,067 - $1.94 Million	233,791 New	233,791 $998,000
Q3 2022 Nov 14, 2022	BUY	$7.17 - $13.87 $711,887 - $1.38 Million	99,287 New	99,287 $954,000
Q1 2022 May 16, 2022	SELL	$10.92 - $16.41 $510,302 - $766,855	-46,731 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$15.81 - $18.99 $810,562 - $973,598	-51,269 Reduced 52.32%	46,731 $745,000
Q3 2021 Nov 15, 2021	BUY	$12.68 - $17.79 $1.24 Million - $1.74 Million	98,000 New	98,000 $1.57 Million
Q4 2020 Feb 16, 2021	SELL	$16.56 - $18.94 $413,503 - $472,931	-24,970 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$17.41 - $19.89 $434,727 - $496,653	24,970 New	24,970 $457,000

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.